Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Pharmaceuticals Ltd.

Division of Johnson & Johnson
www1.actelion.com

Latest From Actelion Pharmaceuticals Ltd.

Novartis Makes Mayzent Case With More MS Data

Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.

 

Neurology Clinical Trials

Mallinckrodt Settles Portion Of DOJ's Acthar Gel Kickback Claims; Charity Copay Probe Continues

$15.4m fine will resolve claims of "wining and dining" doctors to get them to prescribe Acthar. Mallinckrodt dropped NORD and switched to Chronic Disease Fund to administer its copay assistance program, a move that Mallinckrodt’s COO purportedly described as "mom & pop vs. WalMart."

Enforcement Legal Issues

Oncology Dominates As China Drug, Biologic Approvals Surge

China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.

China Approvals

War on C Difficile Is Being Fought On Multiple Fronts

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.

Infectious Diseases Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register